A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 81,201 shares of CERE stock, worth $3.32 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
81,201
Previous 41,000 98.05%
Holding current value
$3.32 Million
Previous $1.74 Million 97.47%
% of portfolio
0.02%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$40.88 - $43.27 $1.64 Million - $1.74 Million
40,201 Added 98.05%
81,201 $3.43 Million
Q4 2023

Feb 14, 2024

BUY
$20.27 - $42.44 $831,070 - $1.74 Million
41,000 New
41,000 $1.74 Million

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Market Cap $6.37B
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.